FDA Approves Imbruvica for Rare Blood Cancer
The U.S. Food and Drug Administration has approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer. Imbruvica is intended for patients with MCL who have received at least one prior therapy. It works by inhibiting the enzyme needed by the cancer to multiply and spread. Imbruvica is the third drug approved to treat MCL. Velcade (2006) and Revlimid (2013) are also approved to treat the disease.
Follow-Up Care for Non-Hodgkin Lymphoma
by Katherine L. Byar, MSN, APN, BC, and Julie M. Vose, MD
Improvements in therapy have increased survival rates for many people with non-Hodgkin lymphoma. However, NHL survivors are still at risk for developing late complications after treatment ends. Routine follow-ups are needed to assess any long-term side effects of therapy and to check for signs of cancer recurrence.
NIH Study Links Hodgkin Lymphoma Treatment to Possible Risk of Stomach Cancer
Hodgkin lymphoma survivors who received certain radiation and chemotherapy regimens were at increased risk of subsequently developing stomach cancer, according to a study by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health.
Cutaneous Lymphoma Foundation
by Susan Thornton
The Cutaneous Lymphoma Foundation, a nonprofit patient advocacy organization, strives to support each person with cutaneous lymphoma by promoting awareness and education, advancing patient care, and facilitating research. Cutaneous lymphoma is a rare form of non-Hodgkin lymphoma that develops in the skin.
Survivor Winner Ethan Zohn on Surviving Hodgkin Lymphoma
by Jessica Webb Errickson
In 2002, Ethan Zohn overcame the elements and pushed his mind and body to the limit, outwitting, outplaying, and outlasting 15 fierce competitors to win the million-dollar prize on Survivor: Africa. Less than a decade later, Ethan would once again have to push his mind and body to the limit in order to survive.
Measuring Your CML Treatment Response
Your doctor needs to monitor your response to drug therapy for chronic myeloid leukemia with blood and bone marrow tests. This is a critically important step to undertake to bring your CML under control. Your test results help your doctor decide whether to increase your drug dose to try for a better response, decrease or stop the drug briefly because of side effects, change to a different drug or drug combination to better control the CML, or change to a different drug or drug combination to manage side effects.
Lower-Dose Treatments for Early-Stage Hodgkin Lymphoma Do Not Compromise Results
In a phase III trial, people with early-stage, low-risk Hodgkin lymphoma who received lower doses of chemotherapy and/or radiotherapy had clinical outcomes that were no worse than those of people who received higher doses.
Emerging Therapies in Non-Hodgkin Lymphoma
Research into the causes, prevention, and treatment of non-Hodgkin lymphoma is being done in many medical centers throughout the world.